Skip to main content

Coeptis Therapeutics pursuing possible acquisition of cell therapy platform

Coeptis did not offer a timeline as to when it expects to conclude its due diligence analysis, which has since begun.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.